中国药业2017，Vol.26Issue(5)：47-48,2.DOI:10.3969/j.issn.1006-4931.2017.05.013
替格瑞洛与氯吡格雷治疗急性冠脉综合征临床疗效及安全性对比
Clinical Efficacy and Safety Comparison of Ticagrelor and Clopidogrel in Treating Acute Coronary Syndrome
欧武华 1刘强 1李东2
作者信息
- 1. 深圳市孙逸仙心血管医院,广东深圳 518020
- 2. 暨南大学第二临床医学院·深圳市人民医院临床药学研究室,广东深圳 518020
- 折叠
摘要
Abstract
Objective To discuss the clinical efficacy and safety of Ticagrelor and Clopidogrel for acute coronary syndrome ( ACS ) . Methods 120 patients of ACS were selected and divided into the study group and the control group, 60 cases in each group. Both groups were given routine treatment. The study group was added with Ticagrelor and the control group was added with Clopidogrel. The clinical efficacy, the incidence of cardiovascular adverse events ( MACE ) and the incidence of adverse events were compared between the two groups. Results The total effective rate was 92. 67% in study group, which was significantly higher than 80. 00% in the control group ( P < 0. 05 );the MACE incidence rate was 2. 00% in the study group, and 2. 67% in the control group, which indicated no significant difference ( P > 0. 05 ) . The incidence of adverse reactions was 3. 33% in the study group, which was significantly lower than 10. 67% in the control group ( P < 0. 05 ) . Conclusion Ticagrelor can improve the clinical symptoms of patients with better efficacy than clopidogrel, can reduce the incidence of adverse reactions in ACS patients and do not increase the risk of bleeding, which is worthy of clinical promotion.关键词
替格瑞洛/氯吡格雷/急性冠脉综合征/临床疗效/安全性评价Key words
Ticagrelor/Clopidogrel/acute coronary syndrome/clinical efficacy/safety evaluation分类
医药卫生引用本文复制引用
欧武华,刘强,李东..替格瑞洛与氯吡格雷治疗急性冠脉综合征临床疗效及安全性对比[J].中国药业,2017,26(5):47-48,2.
